Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A new study from the Smart group has shed light on a key regulatory step in the initiation and progression of Abdominal Aortic Aneurysm by revealing the protective role of a previously little known small protein.

A healthy aorta when compared with an aortic aneursm is significantly narrower and less swollen in appearance.

An abdominal aortic aneurysm (AAA) is a bulging of the aorta, the body’s main blood vessel, which runs from the heart down through the chest and stomach. Prevalence of AAA in the population is high, up to nearly 13% depending on age group, particularly for men aged 65 and over. An AAA can get bigger over time and rupture, causing life-threatening bleeding. There is a high mortality rate of around 80% in patients with ruptured AAA; only dropping to around 50% when patients undergo surgery.  

While clinicians can monitor the beginnings of AAA, a rupture can occur suddenly without warning. Currently, the only available intervention involves a high-risk surgical procedure, which is only undertaken if there is a real danger of rupture. There are no pharmacological treatment options because the underlying causes of AAA are not fully understood.   

Scientists know that in some patients there is a genetic predisposition to AAA, and large genomic studies have identified that mutations in a large protein called LRP1 predispose people to aortic aneurysm, as well as other major vascular diseases. However, the mechanism responsible for how these mutated genes cause the disease has so far been unknown. A new paper from the Smart Group has for the first time demonstrated that a smaller protein called Thymosin β4 (Tβ4) interacts with LRP1 and is ultimately responsible for the behaviour of the smooth muscle cells of the aorta.

Vascular smooth muscle cell differentiation is essential to the development of healthy blood vessels. The smooth muscle cells of the aorta play a crucial role in maintaining its stability and protecting it against disease. In their healthy contractile state, they provide strength and produce the elastin proteins to withstand forces and assist with pumping blood around the body. In disease, damage to the lining of the aorta causes accumulation of fat and allows immune cells to infiltrate vessel walls.  In response, the vessel attempts to repair itself and the smooth muscle cells try to make more smooth muscle. However, in doing so, the cells start to de-differentiate and become less contractile. According to lead researcher Associate Professor Nicola Smart: “They undergo proliferation, presumably with good intentions to try and make more smooth muscle, but actually it makes the problem worse. In doing so, they also break down the elastic layers that keep the vessels stable. These layers are supposed to hold the whole vessel together, keep it tight and keep it strong, and it all breaks apart.”

The reason the smooth muscle cells react in this way is due to their response to different growth factors that are released after injury. These growth factors (notably PDGF-BB) induce a ‘switch’ in the behaviour of the smooth muscle cells; from their contractile state to what’s known as their synthetic or ‘immature’ state, driving them to rapidly multiply and impairing their ability to produce the all-important elastic fibres to protect the aorta. However, it has never been fully understood how their response to the growth factor was controlled.

Through animal studies, the Smart group has found that Tβ4 interacts with LRP1 to control the trafficking of cell receptors for PDGF-BB. Receptors can either be destroyed through the cell’s waste disposal organelles, the lysosomes, which de-sensitises the cell to the effects of a growth factor, or they can be recycled back to the cell surface, which makes the cell more sensitive to the growth factor. Under ideal conditions, this is finely balanced to ensure the right number of receptors are at the cell surface. Tβ4 dictates whether receptors are recycled or degraded. If this protein is not present, too many receptors end up being recycled, the smooth muscle cell becomes hypersensitive and in essence overreacts.

This ultimately suggests that Tβ4 is the key to maintaining smooth muscle in its healthy contractile state, in cooperation with LRP1. Since Tβ4 dictates the fates of cell receptors, it causes a chain of events that determine the sensitivity of the smooth muscle cells in response to growth factors released in the beginnings of aortic aneurysm, and consequently the progression of the disease. Furthermore, Tβ4 is identified as a potential therapeutic target for treating AAA, since a reduction in levels of Tβ4 appears to be detrimental.

Smooth muscle cell with LRP1/PDGRb trafficking through different subcellular compartments

The team were also able to compare their results with AAA samples from the Oxford Abdominal Aortic Aneurysm study. The OxAAA team surgically repair aneurysms in human patients, removing diseased tissue from the lining of the abdomen in the process. Through examining this, the Smart group were able to show that Tβ4 and LRP1 interact in both healthy and diseased patient vessels. Consequently, their study sheds light on a key regulatory step in AAA and identifies a promising new drug target to potentially treat the disease.

The full paper, first authored by Sonali Munshaw, “Thymosin β4 protects against aortic aneurysm via endocytic regulation of growth factor signaling” is available to read in The Journal of Clinical Investigation.

This story is featured on the Oxford Science Blog.

Similar stories

Travels with Vignesh

CRM General

Vignesh Murugesan, a Postdoctoral Researcher in Department of Physiology, Anatomy & Genetics (DPAG), describes how he found his way from the large metropolitan town of Chennai in India to studying regenerative medicine here in Oxford, via an 8 year stint in Sweden.

New MRI technique could detect early signs of heart failure in cancer patients following chemotherapy

CRE Publication Research

New research led by Oxford BHF CRE Intermediate Transition Fellow Dr Kerstin Timm shows that a recently developed imaging technique pioneered by the Tyler Group can detect early metabolic changes in the heart caused by a commonly used chemotherapy drug, which is known to increase risk of heart failure in cancer survivors.

Bone hormone could provide new treatment for heart rhythm disorder

CRE Publication Research

A hormone which helps regulate bone mass is also produced by the heart and could help treat people with a dangerous heart rhythm disorder, according to a new study published in the journal Nature.

Paul Riley appointed Director of Oxford’s Institute of Developmental and Regenerative Medicine

CRM General

Professor Paul Riley will lead the scientific vision of the first institute of its kind in the world to physically merge the disciplines of developmental biology and regenerative medicine in a common goal to treat some of the world’s most prolific diseases.

New study enables identification of people at particular risk of rare, but serious, muscle-related side effect of statin therapy

CRE Publication Research

Researchers at the Nuffield Department of Population Health, in collaboration with other researchers, have published new findings that identify a combination of factors that put some patients at higher risk of myopathy.

HCQ with antibiotics to treat COVID-19 could be dangerous for the heart

CRM General

DPAG researchers have collaborated on an international study that demonstrates a detailed mechanistic understanding of how the anti-malaria drug, Hydroxychloroquine, combined with antibiotics, can cause adverse cardiac side-effects in COVID-19 patients. This gives weight to US Federal advice against using this combined treatment.